The chromosomal translocation [t (9;22)] associated oncogenic fusion protein BCR-ABL drives 90% of chronic myelogenous leukemia (CML). Approximately 9,000 CML diagnosis are expected for 2023. While ...
Son of sevenless homolog 1 (SOS1) is an essential guanine nucleotide exchange factor (GEF) in KRAS-driven tumors, and it also functions as a downstream node protein of BCR-ABL, suggesting its critical ...
BACKGROUND: BCR-ABL tyrosine kinase inhibitors (TKIs) have been increasingly linked to pulmonary arterial hypertension (PAH) since 2009, although supporting evidence is limited. Our objective was to ...
Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...
Expert Rev Anticancer Ther. 2008;8(9):1387-1398. Expert Rev Anticancer Ther. 2008;8(9):1387-1398. © 2008 Expert Reviews Ltd. No writing assistance was utilized in ...
Oncoguide System: A computerized interactive assistance system for the diagnosis and treatment of CML/MPN and MDS D. This is an ASCO Meeting Abstract from the 2016 ASCO Annual Meeting I. This abstract ...
Doctors use molecular responses to monitor the effectiveness of CML treatment. A major molecular response is when the amount of the abnormal BCR–ABL gene in your blood and bone marrow is lowered to ...
Outcomes of veterans diagnosed with chronic myeloid leukemia in the tyrosine kinase inhibitor era. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results